Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Healios KK ( (JP:4593) ) just unveiled an update.
Healios K.K. announced the approval of a patent for its Universal Donor Cells (UDCs) by the Japan Patent Office, marking a significant milestone in the company’s innovation in regenerative medicine. The UDC technology, which reduces immune rejection risks, enhances Healios’ competitive edge globally and positions its UDCs as a potential industry standard, facilitating joint research and licensing agreements worldwide.
The most recent analyst rating on (JP:4593) stock is a Buy with a Yen320.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.
More about Healios KK
HEALIOS K.K. is a leading clinical stage biotechnology company in Japan, focusing on the development of regenerative medicine therapies using stem cells. The company develops proprietary platforms utilizing both somatic stem cells and iPS cells to offer new treatments for diseases lacking effective options. Key projects include invimestrocel for ischemic stroke and trauma, and HLCN061 for solid tumors.
Average Trading Volume: 9,494,617
Technical Sentiment Signal: Buy
Current Market Cap: Yen68.95B
Learn more about 4593 stock on TipRanks’ Stock Analysis page.